Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique joint drug discovery model focused on collaborating with leading academic medical centers to translate and transform concepts into breakthroughs that change patients’ lives.

**CTI Collaborations Include**
- Funding for project-specific research
- Hands-on collaboration from dedicated Pfizer drug-development experts
- Access to scientific/technological expertise and infrastructure at Pfizer
- Potential for in-licensing by Pfizer, which would include milestone and royalty payments
- Publishing rights
- Opportunity for involvement in CTI’s Foundation Alliances

**Pre-proposal Submission Process**
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

All researchers and clinicians whose work meets these criteria are invited to apply. Please submit non-confidential pre-proposals to your Technology Transfer Office by October 21st. For further information about submitting a pre-proposal, please contact Seema Basu at ssbasu@partners.org

**Fall 2019 Areas of Interest and Targets/Pathways of Focus:**

1. Opportunities related to tissue-resident immunity with application in the fields of inflammation, fibrosis, autoimmunity and oncology:
   - Novel molecular or cellular targets with tissue-restricted expression or occurrence that modulate inflammation, immune homeostasis (i.e. tolerance or tumorigenesis)
   - Regulation of non-classical and non-circulating immune cells in human disease progression or prevention
   - Role of tissue-resident macrophages (i.e., synovial, alveolar, adipose etc.) in inflammation, immune homeostasis, or tissue repair
   - Mechanisms of tissue-specific targeting or localization of immune cells and/or therapeutic agents in select peripheral compartments such as gut, liver, skin, and lung

2. Opportunities related to DNA damage response and replicative stress with application in the fields of oncology, immunology, and rare diseases:
   - Chromatin and DNA damage response modulators in the context of nuclear or spatial organization (biochemical condensates)
   - Innovative targets identified via synthetic lethal, chemical biology or other approaches, including DNA repair enzymes, scaffolding factors and nucleic acid targets (R-loops, G-quadruplexes)
   - Senescence, translesion synthesis and other mutagenic repair processes

3. Novel strategies targeting the cause of repeat expansion diseases, including:
   - Those that target the mutant gene
   - Nucleic acid-binding and other small molecules that halt or reverse the somatic expansion of the repeating DNA sequences
   - Novel mechanisms downstream of the pathological repeat, excluding mAbs that clear protein aggregation
   - DNA repair or maintenance mechanisms affecting repeat expansions

**For Information**
For further information about CTI areas of focus, please contact Arpita Maiti at Arpita.Maiti@pfizer.com